Physician profile
Corey M Obrien
NPI 1437321213
$14,659.35
in general payments reported to CMS, 2019-2025
36 companies · $1,774 in 2025
The $1,774 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $584 · 2020: $965 · 2021: $1,160 · 2022: $1,376 · 2023: $4,475 · 2024: $4,325 · 2025: $1,774.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $6,146 · Food and Beverage: $4,428.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $6,146.32 |
| Food and Beverage | $4,427.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $6,016.99 | 2023-2024 | Ion, Da Vinci Surgical System |
| Astrazeneca Pharmaceuticals LP | $1,867.35 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Grifols USA, LLC | $1,239.76 | 2019-2025 | Prolastin-C Liquid, Xembify |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,119.93 | 2019-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Glaxosmithkline, LLC. | $846.38 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Regeneron Healthcare Solutions, INC. | $572.96 | 2020-2025 | Dupixent |
| Genzyme Corporation | $567.19 | 2019-2025 | |
| Mylan Specialty L.P. | $381.48 | 2019-2024 | Yupelri |
| Insmed, INC. | $366.35 | 2019-2025 | Arikayce, Brinsupri |
| Jazz Pharmaceuticals INC. | $234.65 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $183.99 | 2020-2024 | |
| Actelion Pharmaceuticals US, INC. | $142.37 | 2021-2024 | Opsumit, Uptravi |
| Merck Sharp & Dohme LLC | $125.23 | 2019-2025 | Zerbaxa, Dificid, Recarbrio |
| United Therapeutics Corporation | $99.05 | 2021-2025 | Tyvaso, Tyvaso |
| Viatris Specialty LLC | $98.83 | 2025 | Yupelri |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $79.75 | 2019-2025 | Xolair |
| Verona Pharma, INC. | $77.68 | 2025 | Ohtuvayre |
| Inspire Medical Systems, INC. | $76.32 | 2024 | Inspire |
| Avadel Cns Pharmaceuticals, LLC | $62.26 | 2024-2025 | Lumryz |
| Philips North America LLC | $62.20 | 2024-2025 | Vest Therapy Und, (8874) Incourage |
| Harmony Biosciences LLC | $54.80 | 2022-2025 | |
| Teva Pharmaceuticals USA, INC. | $53.81 | 2020 | |
| Amgen INC. | $48.22 | 2023-2025 | Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $44.62 | 2023 | Glassia, Gammagard |
| Electromed, INC. | $42.19 | 2019-2023 | Smartvest |
| Axsome Therapeutics, INC. | $28.17 | 2025 | Sunosi |
| Resmed Corp | $23.06 | 2023 | |
| Melinta Therapeutics, LLC | $21.27 | 2021 | |
| Advanced Respiratory, INC | $18.76 | 2020 | |
| Circassia INC. | $17.95 | 2020 | |
| Alexion Pharmaceuticals, INC. | $15.38 | 2023 | Ultomiris |
| Paratek Pharmaceuticals, INC. | $15.32 | 2022 | |
| La Jolla Pharmaceutical Company | $15.23 | 2020 | |
| Mallinckrodt Enterprises LLC | $14.79 | 2019 | |
| Covidien LP | $13.38 | 2020 | |
| Pulmonx Corporation | $11.68 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Corey Obrien listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.